{
  "document_info": {
    "file_name": "tmp1czm2b82.pdf",
    "file_path": "/private/var/folders/74/gmbqttjd55jdp5rkths5nhj80000gn/T/tmp1czm2b82.pdf",
    "file_size_bytes": 724940,
    "uploaded_file_id": "file-AaE5EymHfS966gWS7BNczs",
    "content_hash": "45a2637b23af0c79117408aca590af18dc85f965683b9369ce51ca2bd36c6fd7",
    "file_id_cache_hit": false,
    "model": "gpt-5-nano-2025-08-07",
    "evaluated_at": "2025-09-30T15:03:58.684125",
    "run_id": "20250930_150358"
  },
  "evaluation_summary": {
    "total_requirements": 10,
    "compliance_score": 60.0,
    "status_counts": {
      "PASS": 6,
      "FAIL": 0,
      "FLAGGED": 4,
      "NOT_APPLICABLE": 0,
      "ERROR": 0
    },
    "total_tokens_used": 217677,
    "estimated_cost_usd": 1.0884
  },
  "requirements_results": [
    {
      "status": "PASS",
      "confidence": 0.85,
      "rationale": "PMS system/procedures are defined and active/post-production information is to be collected and reviewed. Responsibilities are defined (QA, Product Development, Regulatory Affairs). The document cites methods and sources for post-market data collection (complaint handling, production data, user feedback, supply chain, public information) and requires periodic reviews of residual risk and PMS activity. Evidence references ISO14971/PMS-related clauses in the Risk Management SOP (sections 5.12, 5.2.8, 5.11.1.4, 5.13) and responsibilities in Section 2.",
      "evidence": [
        "5.12.1 Information relevant to the combination product shall be actively collected and reviewed in the production and post-production phases to comply with post market surveillance regulations as well as to use the data to provide input to the risk management file for the device being marketed. This information is collected in the Post Market Surveillance and Complaint Handling Process.",
        "5.12.2 Information collected and reviewed about the combination product shall entail the following, at a minimum: 5.12.2.1 Information generated during production and monitoring of the production process; 5.12.2.2 Information generated by the user; 5.12.2.3 Information generated by those accountable for the installation, use and maintenance of the combination product (as applicable); 5.12.2.4 Information generated by the supply chain; 5.12.2.5 Publicly available information; 5.12.2.6 Information related to the generally acknowledged state of the art.",
        "5.12.3 The information collected shall be reviewed for possible relevance to safety, especially with respect to the following: 5.12.3.1 Previously unrecognized hazards or hazardous situations are present; 5.12.3.2 An estimated risk arising from a hazardous situation is present; 5.12.3.3 The overall residual risk is no longer acceptable in relation to the benefits of the intended use; 5.12.3.4 The generally acknowledged state of the art has changed.",
        "5.11.1.4 The risk management process shall be reviewed as part of the management review; Appropriate methods to collect and review the information in the production and post-production phases have been determined and are in place.",
        "5.2.8.1 At a minimum, data from the complaint handling process, if applicable, shall be used as part of the residual risk analysis."
      ],
      "gaps": [
        "The artifacts listed in the acceptance criteria (PMS Plan, Complaint Handling SOP, Vigilance/Field Action procedures, data pipelines) are not explicitly named as separate, standalone documents in the excerpt; references are to processes (Post Market Surveillance and Complaint Handling Process) rather than discrete documents.",
        "No explicit diagram or description of data pipelines; information flow is described in narrative form without a dedicated PMS data architecture diagram."
      ],
      "recommendations": [
        "Create or designate an explicit PMS Plan document and link it to the QMS (to satisfy the 'PMS Plan' artifact requirement).",
        "Develop and approve separate Complaint Handling SOP and Vigilance/Field Action procedures, and map them to the references in 5.12/5.2.8 (PMS inputs and regulatory reporting).",
        "Include a formal data pipeline/data flow diagram showing how production, user, maintenance, supply chain, and public information feed into the risk management system and PMS outputs.",
        "Document the tools and access controls (e.g., QMS, document management system) used to collect, review, and store PMS data (reference QAP001 for document control).",
        "Schedule and document periodic PMS reviews and management reviews per 5.13, ensuring actions are captured in the Risk Management Report."
      ],
      "requirement_id": "ISO14971-10.1-01",
      "requirement_title": "System for P&PP monitoring",
      "requirement_clause": "10.1",
      "tokens_used": 21408
    },
    {
      "status": "PASS",
      "confidence": 0.78,
      "rationale": "The document demonstrates systematic information collection from the sources listed in ISO14971-10.2 (production/process monitoring, user/servicing feedback, supply chain inputs, publicly available information, and state of the art) and requires ongoing review and post-market surveillance. It also documents periodic risk management reviews and consideration of information from similar products, literature, and other sources, fulfilling the acceptance criteria for routine ingestion, literature/signal review, and competitor/alternative monitoring.",
      "evidence": [
        "\"5.12 Production and Post-Production Activities\"",
        "\"5.12.1 Information relevant to the combination product shall be actively collected and reviewed in the production and post-production phases to comply with post market surveillance regulations as well as to use the data to provide input to the risk management file for the device being marketed. This information is collected in the Post Market Surveillance and Complaint Handling Process.\"",
        "\"5.12.2 Information collected and reviewed about the combination product shall entail the following, at a minimum: 5.12.2.1 Information generated during production and monitoring of the production process 5.12.2.2 Information generated by the user 5.12.2.3 Information generated by those accountable for the installation, use and maintenance of the combination product (as applicable) 5.12.2.4 Information generated by the supply chain 5.12.2.5 Publicly available information 5.12.2.6 Information related to the generally acknowledged state of the art.\"",
        "\"5.12.3. The information collected shall be reviewed for possible relevance to safety, especially with respect to the following: 5.12.3.1 Previously unrecognized hazards or hazardous situations are present 5.12.3.2 An estimated risk arising from a hazardous situation is present 5.12.3.3 The overall residual risk is no longer acceptable in relation to the benefits of the intended use 5.12.3.4 The generally acknowledged state of the art has changed.\"",
        "\"5.12.4 If any of these conditions occur, the following activities shall be performed: 5.12.4.1 The risk management file shall be reviewed to determine if reassessment of risks and/or assessment of new risks is necessary. 5.12.4.2 If a residual risk is no longer acceptable, the impact on previous implemented risk control measures shall be evaluated and should be considered as an input for modification of the combination product 5.12.4.3 Consider the need for actions regarding combination products on the market 5.12.4.4 Evaluate the impact on previously implemented risk management activities 5.12.4.5 The results of the evaluation as input for the review of suitability of the risk management process by top management, as noted in Section 5.13.3.\"",
        "\"5.6.3.3.1. The risk analysis shall identify and document the known and foreseeable hazards associated with the combination product based on the intended use, reasonably foreseeable misuse and the characteristics related to safety... 5.6.3.3.1. Review of the same or similar combination products (internally or externally), adverse event (AE) databases, publications, and other sources.\"",
        "\"5.9.5.2. If a residual risk is deemed unacceptable using the criteria established in the risk management plan and further risk control is not practicable, the Applicant may gather and review data and literature to determine if the benefits of the intended use outweigh this residual risk.\"",
        "\"5.13.1 Periodic reviews of risk management documentation shall be conducted as a post market activity on an annual basis or as specified by the team and documented in the risk management plan or when events that may impact the original risk management decision occur.\"",
        "\"5.13.3.The risk management process shall be reviewed as part of the management review following requirements in XX-YYY, Management Responsibility. At a minimum, the review shall include: 5.13.3.1. Risk management process 5.13.3.2. Summaries of responses for critical and high risks 5.13.3.3. Risk profile(s).\"",
        "\"5.2.8 The risk management plan shall include documentation of decisions, based on risk analysis, about what sort of post-market surveillance is appropriate for the combination product. For example, whether reactive surveillance is adequate or whether proactive studies are needed.\"",
        "\"5.2.7.2 Other potential sources of verification/validation information include, but are not limited to scientifically valid characterization studies.\""
      ],
      "gaps": [
        "Explicit phrase 'competitor/alternative therapy monitoring' is not used; evidence is inferred from 'similar products' and external sources (5.6.3.3.1)."
      ],
      "recommendations": [
        "Formalize a dedicated competitor/alternative therapy monitoring process and logs to explicitly satisfy ISO14971-10.2 expectations.",
        "Maintain explicit literature review logs and post-market surveillance logs as artifacts (in addition to the risk management file) to demonstrate routine ingestion and periodic reviews.",
        "Ensure supplier quality records and service logs are captured and linked to risk management outputs (e.g., hazard analyses, FMEAs, risk management reports) for traceability."
      ],
      "requirement_id": "ISO14971-10.2-01",
      "requirement_title": "Information collection - sources",
      "requirement_clause": "10.2",
      "tokens_used": 23960
    },
    {
      "status": "FLAGGED",
      "confidence": 0.6,
      "rationale": "The provided Risk Management Program SOP (QAP013.01) contains comprehensive RM processes (hazard analysis, risk estimation/evaluation, risk control, residual risk, RM file, periodic reviews) and references to post-production information and management review, which align with updating hazard analyses and RM artifacts. However, there is no explicit evidence of signal management activities (signal review minutes, signal management SOP), documented triggers for escalation, nor an explicit CAPA process within the RM context. This leaves gaps relative to Acceptance Criteria (Signal review minutes; triggers documented; updates to hazard analysis/RMP; CAPA as needed). See evidence sections below for specific clause references. ",
      "evidence": [
        "5.3.1. For the combination product being considered, a risk management file shall be established and maintained throughout the product lifecycle.",
        "5.3.4. The risk management file consists of the following deliverables, at a minimum: 5.3.4.1 Hazard Analysis; 5.3.4.2 Risk Management Plan; 5.3.4.3 Risk Analyses (internal and external); 5.3.4.5 Risk Management Report(s); 5.3.4.7 Any supporting or referenced documents or records of activities required by the risk management plan.",
        "5.11.1. Prior to release for clinical usage or commercial production of the combination product, the applicant shall review the execution of the risk management plan. This review shall ensure the following, at a minimum: 5.11.1.6 Top management ... approve the risk management report if the benefit risk assessment is needed to justify release of the product according to established risk thresholds.",
        "5.12.3. The information collected shall be reviewed for possible relevance to safety, especially with respect to the following: 5.12.3.1 Previously unrecognized hazards or hazardous situations are present; 5.12.3.2 An estimated risk arising from a hazardous situation is present; 5.12.3.3 The overall residual risk is no longer acceptable in relation to the benefits of the intended use; 5.12.3.4 The generally acknowledged state of the art has changed.",
        "5.13.1. Periodic reviews of risk management documentation shall be conducted as a post market activity on an annual basis or as specified by the team and documented in the risk management plan or when events that may impact the original risk management decision occur.",
        "5.2.11. Unplanned risk management activities (ad hoc) may be required during the product lifecycle. These unplanned activities shall comply with this procedure and shall be included in the risk management file.",
        "5.9.4.1. After the risk control measures are implemented, the applicant shall evaluate the residual risk using the criteria for risk acceptability defined in the risk management plan. The results of this evaluation shall be recorded in the Hazards Analysis and/or the FMEAs.",
        "5.9.5.1. A benefit-risk analysis shall be performed to determine the acceptability of each individual risk and the overall residual risk of the combination product; 5.9.5.2\u20135.9.5.4 describe further actions if residual risk is unacceptable (data/literature review, modification, etc.)."
      ],
      "gaps": [
        "No explicit Signal Management SOP provided in the document; no signal review minutes or signal escalation workflow evident.",
        "No formally documented triggers for escalation or signal-driven CAPA workflow within the RM context.",
        "CAPA terminology and a dedicated CAPA workflow are not explicitly described; risk management actions exist but not a standalone CAPA process.",
        "No explicit linkage or template for Signal Management as an artifact to satisfy the expected artifacts (Signal management SOP; safety review board minutes)."
      ],
      "recommendations": [
        "Develop and attach a Signal Management SOP and a standardized template for Signal Review Minutes to capture triggers, review cadence, escalation, and CAPA links.",
        "Implement a formal CAPA process within the RM framework (including initiation criteria, investigation, root cause analysis, corrective/preventive actions, verification/closure criteria, and linkage to the Risk Management File).",
        "Map trigger events to RM artifacts: ensure triggers (e.g., new safety information, post-market data, design changes) automatically generate RM updates and CAPA records where appropriate.",
        "Provide templates or references to RM updates (Hazard Analysis updates, Risk Management Plan revisions, and Risk Management Reports) tied to signal findings and CAPA resolutions; include example escalation paths in the SOP.",
        "Consider including a dedicated section or appendix describing signal flow from production/post-production information (5.12) to hazard re-evaluation and risk control updates (5.6\u20135.10)."
      ],
      "requirement_id": "ISO14971-10.3-01",
      "requirement_title": "Information review & escalation",
      "requirement_clause": "10.3",
      "tokens_used": 21287
    },
    {
      "status": "PASS",
      "confidence": 0.87,
      "rationale": "The ISO14971-4.1 risk management requirements are addressed by a formal Risk Management Program (QAP013.01) with lifecycle coverage, documentation, and cross-references to related QMS processes. Evidence shows: scope across the product lifecycle (1.2); lifecycle elements (5.1.4); process map evidenced by Figure 1 (5.1.5); risk management file controls (5.3.5); integration with Design Control (5.1.2); and post-production activities (5.12) including risk management continuation and reviews (5.13). Additionally, artifact expectations (Risk Management SOP, process flowchart, QMS cross-references) are supported by sections detailing the Risk Management File, Plan, and cross-references to QAP001/QAP012.",
      "evidence": [
        "1.2 Scope: This SOP applies to the commercial and investigational (clinical) combination products designed, manufactured, and distributed under Current Good Manufacturing Practice (cGMP) conditions throughout the product lifecycle phases, including product development, technology and design transfer, manufacturing, product surveillance and product discontinuation.",
        "5.1.4 The risk management process includes the following elements throughout the product life cycle: 5.1.4.1 Identifying hazards and hazardous situations associated with the combination product; 5.1.4.2 Estimating and evaluating the associated risks; 5.1.4.3 Controlling risk and monitoring the effectiveness of the risk control measures; 5.1.4.4 Monitoring the effectiveness of the risk control measures; 5.1.4.5 Risk reviews driven by new information; 5.1.4.6 Periodic review of identified risks.",
        "5.1.5 Figure 1 illustrates the systemic representation of the risk management process.",
        "5.3.5 The contents of the risk management file (documents, records, trace items, etc.) shall be controlled and maintained in the document management system in accordance with QAP001, Format, Content, Approval and Issuance of Controlled Documents.",
        "5.1.2 Risk management is integrated within QAP012, Design Control as part of product realization.",
        "5.12 Production and Post-Production Activities: 5.12.1 Information relevant to the combination product shall be actively collected and reviewed in the production and post-production phases to comply with post market surveillance regulations as well as to use the data to provide input to the risk management file for the device being marketed. 5.12.2 Information collected and reviewed about the combination product shall entail the following: 5.12.2.1 Information generated during production and monitoring of the production process; 5.12.3 The information collected shall be reviewed for possible relevance to safety, especially 5.12.3.1 previously unrecognized hazards or hazardous situations are present; 5.12.3.3 The overall residual risk is no longer acceptable in relation to the benefits of the intended use; 5.12.4 If any of these conditions occur, the following activities shall be performed: 5.12.4.1 The risk management file shall be reviewed to determine if reassessment of risks and/or assessment of new risks is necessary; 5.12.4.5 The results of the evaluation shall be provided as input for the review of suitability of the risk management process by top management, as noted in Section 5.13.3.",
        "5.11.1 Prior to release for clinical usage or commercial production of the combination product, the applicant shall review the execution of the risk management plan. This review shall ensure the following, at a minimum: 5.11.1.1 The risk management plan has been appropriately implemented. 5.11.1.2 The risk management process has been appropriately implemented in accordance with this procedure. 5.11.1.3 The overall residual risk acceptability and overall benefit risk analysis have been determined.",
        "Appendix references: The procedure cross-references QAP012 Design Control and QAP001 Document Control for lifecycle and document control alignment.",
        "5.13 Periodic Reviews: 5.13.1 Periodic reviews of risk management documentation shall be conducted as a post market activity on an annual basis or as specified by the team and documented in the risk management plan or when events that may impact the original risk management decision occur.",
        "5.3 Risk Management File: 5.3.1 For the combination product being considered, a risk management file shall be established and maintained throughout the product lifecycle. 5.3.4 The risk management file consists of hazard analysis, risk management plan, risk analyses, benefit risk analysis, risk management report(s), post-production risk management report(s) (when appropriate), and supporting documents."
      ],
      "gaps": [],
      "recommendations": [
        "Maintain explicit cross-references in the Quality Manual to QAP012 (Design Control) and QAP001 (Document Control) to ensure ongoing traceability of risk management activities within product realization and document control.",
        "Consider including a formal process flowchart in the Quality Manual to complement Figure 1 and satisfy artifact expectations (process map/flow with all required elements).",
        "Periodically verify that life-cycle coverage remains explicit in all risk management activities as products transition between lifecycle phases, updating the Risk Management Plan accordingly."
      ],
      "requirement_id": "ISO14971-4.1-01",
      "requirement_title": "Risk management process established",
      "requirement_clause": "4.1",
      "tokens_used": 22081
    },
    {
      "status": "PASS",
      "confidence": 0.78,
      "rationale": "The document demonstrates top management commitment and defined roles, plus training plan references. Evidence includes explicit resource assignment for risk management, defined roles across functions, top management approval requirements, and a training program reference. These align with ISO14971-4.2 acceptance criteria.",
      "evidence": [
        "Section 2.1 Role Responsibility: 'Assures adequate resources and assignment of competent personnel for risk management'.",
        "Section 5.11.1.6: 'Top management of Product Development, Clinical Development, Regulatory Affairs, and QA must approve the risk management report if the benefit risk assessment is needed to justify release of the product according to established risk thresholds.'",
        "Section 5.13.3: 'The risk management process shall be reviewed as part of the management review.'",
        "Section 5.1.8: 'Appropriate competence and training program requirements are described in QAP011, GMP Training Program.'"
      ],
      "gaps": [
        "No explicit management review minutes or documented management review records are provided in the excerpt.",
        "No standalone organizational chart or formal resource plan is presented in the shown content."
      ],
      "recommendations": [
        "Attach or reference actual management review minutes and explicit resourcing decisions to demonstrate documented top management commitment.",
        "Include or attach organizational charts and a formal resource plan for risk management as artifacts.",
        "Maintain a formal training plan in the risk management records showing completed training for risk management personnel."
      ],
      "requirement_id": "ISO14971-4.2-01",
      "requirement_title": "Top management commitment",
      "requirement_clause": "4.2",
      "tokens_used": 21033
    },
    {
      "status": "PASS",
      "confidence": 0.82,
      "rationale": "The document embeds a risk acceptability policy within the Risk Management Program/SOP. It specifies that criteria for risk acceptability are defined and documented in the Risk Management Procedure, requires top management to set thresholds, cites regulatory/standards inputs, allows risk management planning at product or family level, and assigns responsibilities to QA, Regulatory, Clinical Development, etc.\u2014all of which satisfy the acceptance criteria for policy existence, regulatory/standard inputs, principle definitions (including per product family when applicable), and accessibility via formal procedures and roles.",
      "evidence": [
        "2.1. The responsibility statements include: \"Defines and documents criteria for risk acceptability in the Risk Management Procedure. This provides a framework that ensures that criteria are based upon applicable national or regional regulations and relevant International Standards and considers available information such as the general acknowledged state of the art and known stakeholder concerns.\"",
        "3. References: \"21CFR820.30; ISO 14971: 2019; ISO 12971: 2020; Viking QAP012 Design Control; ISO 62366: 2005\"",
        "5.2.3.2.2: \"Top management of Product Development, Clinical Development, Regulatory Affairs and QA establish acceptable thresholds for residual risk acceptance within this procedure.\"",
        "5.2.5: \"Categories of risk and criteria for risk acceptability, in accordance with this procedure, including criteria for accepting risks when the probability of occurrence of harm cannot be estimated. The risk acceptance criteria are based on the following decisions: 5.2.5.1. The risk presented by the current standard of care 5.2.5.2. The potential health benefits of using the combination product 5.2.5.3. The generally acknowledged state of the art defined in recognized consensus standards\"",
        "5.2.6: \"The evaluation method and criteria for acceptability for the overall residual risk, considering all the impact of all risks together, shall be clearly defined and documented in the risk management plan.\"",
        "5.2.10: \"The risk management plan may be developed for a specific product or for a family of similar products, as appropriate.\"",
        "2. Responsibilities (Role Responsibility table) notes that top management defines and documents risk acceptability criteria and ensures policies are established and followed, demonstrating accessible governance and alignment with teams.",
        "5.3.4.5: \"Risk Management Report(s)\" and related risk management artifacts indicate where acceptability decisions and their documentation reside within team processes."
      ],
      "gaps": [
        "No explicit standalone 'Risk Acceptability Policy' document with a visible approval stamp is shown; the policy is embedded within the Risk Management Procedure (2.1) rather than as a separate policy artifact.",
        "Device-family specific acceptability criteria are supported conceptually (5.2.10 and 5.2.5), but the document does not provide concrete, example criteria for particular device families within this policy; would benefit from explicit family-level criteria in RMPs or an appended policy.",
        "Explicit statement of distribution/availability to all relevant teams is not directly shown (e.g., distribution list, training, or intranet location); relies on standard SOP distribution practices rather than a stated accessibility mechanism.",
        "No explicit cross-reference to an operating mechanism for maintaining and communicating an updated risk acceptability policy aside from periodic reviews (5.13) and risk management plan updates."
      ],
      "recommendations": [
        "Create and publish a standalone Risk Acceptability Policy document with formal approval, versioning, and a clear distribution/communication plan to teams.",
        "Document device-family specific risk acceptability criteria within each Risk Management Plan or add a dedicated annex for device family criteria, including thresholds and decision rules.",
        "Establish and document explicit accessibility mechanisms (e.g., intranet posting, training records, distribution lists) confirming that the policy and related risk acceptance criteria are readily accessible to all affected teams.",
        "Link the Risk Acceptability Policy to RMPs and ensure periodic reviews (in line with 5.13) include revalidation of acceptability criteria and update cross-references to ISO 14971/TR 24971 guidance where applicable."
      ],
      "requirement_id": "ISO14971-4.2-02",
      "requirement_title": "Policy for risk acceptability",
      "requirement_clause": "4.2",
      "tokens_used": 23864
    },
    {
      "status": "PASS",
      "confidence": 0.9,
      "rationale": "Acceptance Criteria satisfied: the document establishes periodic reviews (inputs/outputs, action tracking) and a pathway for updates to risk management documentation. Evidence shows explicit periodic review requirements, management review inclusion, and triggers for updates. See: Periodic review cadence (5.13.1), review of risk management reports when file elements change (5.13.2), management-review criteria (5.13.3), pre-release risk management report contents and approvals (5.11.1), management oversight and improvement obligation (5.1.6), periodic risk management plan reviews (5.2.12), and post-production inputs triggering reassessment (5.12.4). These collectively demonstrate inputs/outputs, action tracking, and updates to procedures as needed.",
      "evidence": [
        "5.13.1 Periodic reviews of risk management documentation shall be conducted as a post market activity on an annual basis or as specified by the team and documented in the risk management plan or when events that may impact the original risk management decision occur.",
        "5.13.2 Periodic review of risk management reports shall be conducted, when elements in the risk management file change, to assess the acceptability of residual risks and the overall residual risk of the combination product.",
        "5.13.3 The risk management process shall be reviewed as part of the management review following requirements in XX-YYY, Management Responsibility. At a minimum, the review shall include: 5.13.3.1. Risk management process 5.13.3.2. Summaries of responses for critical and high risks 5.13.3.3. Risk profile(s).",
        "5.11.1 Prior to release for clinical usage or commercial production of the combination product, the applicant shall review the execution of the risk management plan. This review shall ensure the following, at a minimum: 5.11.1.1 The risk management plan has been appropriately implemented. 5.11.1.2 The risk management process has been appropriately implemented in accordance with this procedure. 5.11.1.3 The overall residual risk acceptability and overall benefit risk analysis have been determined. 5.11.1.4 Appropriate methods to collect and review the information in the production and post-production phases have been determined and are in place. 5.11.1.5 Requirements for disclosure of overall and individual residual risks through product labeling and other forms of user communication have been determined. 5.11.1.6 Top management of Product Development, Clinical Development, Regulatory Affairs, and QA must approve the risk management report if the benefit risk assessment is needed to justify release of the product according to established risk thresholds.",
        "5.1.6 As a check on the effectiveness of the risk management processes defined, management shall regularly review the outputs of processes, products, services, and the quality system, and make improvements as needed, in accordance with the Management Review Process specified in XX-YYY, Management Responsibility.",
        "5.2.12 The risk management plan shall be reviewed periodically at specified time intervals.",
        "5.12.4 If any of these conditions occur, the following activities shall be performed: 5.12.4.1 The risk management file shall be reviewed to determine if reassessment of risks and/or assessment of new risks is necessary.",
        "5.2.13 During product development, the risk management plan review requirements shall be specified in the design and development plan. After the product is released to market, the risk management file shall be reviewed."
      ],
      "gaps": [
        "Explicit reference to CAPA/change control tickets as risk-management artifacts is not present; the document refers to risk management files, risk management plans, and risk reviews but does not name CAPA tickets or a formal change-control ticketing system (see 5.11.x, 5.12.x, 5.13.x for review/update workflows).",
        "No direct sample artifacts or templates for CAPA/change-control tickets are shown in the provided excerpts; availability of such artifacts would strengthen evidence of formal action tracking beyond risk management file entries."
      ],
      "recommendations": [
        "Add or reference explicit CAPA/change-control ticketing artifacts within the risk management framework (e.g., CAPA IDs, change-control ticket numbers, status, and closure evidence) to satisfy expectations for action-tracking artifacts.",
        "Include a concrete cross-reference in the Risk Management File to CAPA/Change Control tickets and tie them to 5.13 periodic reviews and 5.12 post-production evaluations for traceability.",
        "Consider adding explicit language in the SOP to require updating controlled documents (RMP, Hazard Analysis, FMEA) upon CAPA/Change Control closures and to document these updates in the revision history."
      ],
      "requirement_id": "ISO14971-4.2-03",
      "requirement_title": "Suitability review of the process",
      "requirement_clause": "4.2",
      "tokens_used": 21587
    },
    {
      "status": "FLAGGED",
      "confidence": 0.58,
      "rationale": "The document acknowledges competence requirements for risk management tasks and references an existing training program (QAP011) but does not provide explicit artifacts required by the acceptance criteria. Specifically, there is no visible training matrix, CVs/experience records, or defined role-based competency profiles within this document. Evidence found: (i) 5.1.8 states competence requirements and references QAP011 for training; (ii) 2.1 outlines responsibilities and roles but does not define competency profiles. The expected artifacts (training records; CVs; competency matrices) are not shown in the attached text/images.",
      "evidence": [
        "5.1.8. Persons performing risk management tasks have the knowledge and experience appropriate to the tasks assigned to them. These shall include, where appropriate, knowledge and experience of the particular combination product (or similar products) and its use, the technologies involved, or the risk management techniques. Appropriate competence and training program requirements are described in QAP011, GMP Training Program.",
        "2.1. Viking Therapeutics Product Development and Quality Assurance (QA) are responsible for ensuring compliance with this SOP. All functional leads/managers are responsible for ensuring compliance with the applicable segments of this procedure that are within their areas of responsibility."
      ],
      "gaps": [
        "No explicit training matrix present in the document.",
        "No training records shown or referenced as attached within this SOP.",
        "No CVs/experience records for personnel performing risk management tasks are provided.",
        "No role-based competency profiles defined or linked to specific risk management duties within this document."
      ],
      "recommendations": [
        "Include or attach a formal Training Matrix mapping personnel to specific risk management tasks, with completion dates and competency levels, in the Risk Management File (per 5.3.x and 5.2.x).",
        "Capture and attach CVs/experience records for personnel assigned to risk management tasks, or document a standardized method to verify qualifications in the competency profiles.",
        "Develop and include explicit role-based competency profiles (e.g., for Product Development, QA, Regulatory Affairs, Clinical Development) with required education, training, and experience, and reference these in QAP011 as applicable.",
        "Ensure cross-references to QAP011 and any other related training/qualification templates are included in the Risk Management Plan and Risk Management File, and maintain evidence of competency verification as part of the risk management records."
      ],
      "requirement_id": "ISO14971-4.3-01",
      "requirement_title": "Competence of personnel",
      "requirement_clause": "4.3",
      "tokens_used": 19951
    },
    {
      "status": "FLAGGED",
      "confidence": 0.62,
      "rationale": "The document describes requirements for a Risk Management Plan (RMP) and lifecycle coverage, meeting some criteria but not all. The text includes a clear requirement that the RMP include the scope of planned risk management activities and specify lifecycle phases for each plan element. Evidence: 5.2.3.1 states: \"The scope of the planned risk management activities, identifying and describing the combination product (or product family), intended use, interfaces with external systems or processes, and the lifecycle phases for which each element of the plan is applicable.\" However, the provided content does not include an actual named device and version, nor a dedicated lifecycle applicability matrix/table mapping plan elements to lifecycle phases. Evidence suggests the SOP describes how an RMP should be structured, but no specific device name, version (e.g., RMP vX), or a lifecycle applicability table is shown in the attached pages. See also the Risk Management File sections (5.3.x) indicating the RMP is an intended deliverable, but not listing a concrete matrix. Evidence: 5.3.1\u20135.3.6; Figure 1 Risk Management Overview. ",
      "evidence": [
        "\"5.2.3.1. The scope of the planned risk management activities, identifying and describing the combination product (or product family), intended use, interfaces with external systems or processes, and the lifecycle phases for which each element of the plan is applicable\"",
        "Figure 1. Risk Management Overview",
        "5.3.4. The risk management file consists of the following deliverables, at a minimum: 5.3.4.1. Hazard Analysis; 5.3.4.2. Risk Management Plan"
      ],
      "gaps": [
        "No explicit device name and version are provided for the RMP in the attached content.",
        "No explicit lifecycle applicability matrix/table mapping risk management plan elements to lifecycle phases is visible in the attached content.",
        "No artifact labeled 'Risk Management Plan (RMP) vX' or a lifecycle applicability table is presented in the provided pages."
      ],
      "recommendations": [
        "Provide the actual Risk Management Plan document for the device with a specific version (e.g., RMP vX) and explicitly name the device.",
        "Include a dedicated lifecycle applicability matrix/table in the RMP that maps each risk management plan element to the lifecycle phases (design, development, production, post-production, etc.).",
        "Add a lifecycle coverage table or matrix (or explicitly reference an attached lifecycle applicability table) to satisfy ISO14971-4.4(a) requirements."
      ],
      "requirement_id": "ISO14971-4.4-01",
      "requirement_title": "RMP scope & lifecycle coverage",
      "requirement_clause": "4.4(a)",
      "tokens_used": 20694
    },
    {
      "status": "FLAGGED",
      "confidence": 0.58,
      "rationale": "The document shows explicit assignment of responsibilities and authorities at the function/role level and approval responsibilities by top management, satisfying parts of ISO14971-4.4(b). However, there is no explicit, named RACI chart table mapping each risk-management activity to Responsible/Accountable/Consulted/Informed roles, only general role-based responsibilities and statements about sharing responsibilities. Therefore, acceptance criteria are only partially satisfied. See evidence below.",
      "evidence": [
        "2.1. Viking Therapeutics Product Development and Quality Assurance (QA) are responsible for ensuring compliance with this SOP.",
        "Role Responsibility Functional Area Management (Product Development, Clinical Development, Regulatory Affairs and Quality Assurance Management) \u2022 Responsible for ensuring that the risk management process is followed within area of responsibility \u2022 Provides subject matter expertise, as appropriate, to risk management activities \u2022 Ensures execution of risk reduction activities \u2022 Creates and maintains risk management documentation",
        "Role Responsibility  Quality Assurance Management \u2022 Overall responsibility for effective execution and oversight of risk management process, including both internal and external organizations\u2019 scope of work.",
        "5.2.3.2 Assignment of responsibilities and authorities for the execution of specific risk management activities throughout the product lifecycle shall include: 5.2.3.2.1 Identification by function or area of expertise the necessary reviewers, contributors, and personnel responsible for risk management execution throughout the product lifecycle",
        "5.2.3.2.2 Top management of Product Development, Clinical Development, Regulatory Affairs and Quality Assurance establish acceptable thresholds for residual risk acceptance within this procedure.",
        "5.2.3.2.4 Risk management responsibilities may be shared with design partners, consultants, contract manufacturers or suppliers, if applicable. The risk management plan shall identify the shared risk management activities, responsible party(ies), controlling procedure(s) and controlling location(s)/documentation system(s).",
        "5.11.1.6 Top management of Product Development, Clinical Development, Regulatory Affairs, and QA must approve the risk management report if the benefit risk assessment is needed to justify release of the product according to established risk thresholds."
      ],
      "gaps": [
        "No explicit RACI chart/table is visible in the provided text (no per-activity R, A, C, I mapping).",
        "No named individuals are listed as owners/approvers for each discrete risk-management activity beyond functional-area roles; no per-activity responsibility matrix is shown.",
        "No dedicated signatures block or explicit approval signatures for risk management documents are visible in the excerpt (only general top-management approval statements)."
      ],
      "recommendations": [
        "Add a formal RACI matrix in the Risk Management Plan (5.2.3.x) mapping each risk-management activity (e.g., hazard identification, risk estimation, risk evaluation, risk control, residual risk evaluation, benefit-risk analysis, post-market surveillance) to specific Owners (Responsible), a single Approver (Accountable), and any Consulted/Informed parties.",
        "Include a signatures/approval section for risk management artifacts (e.g., Risk Management Plan, Hazard Analysis, Risk Analyses, Risk Management Report) with dates and responsible approvers.",
        "Where feasible, assign named individuals or specific roles to each activity to enable traceability and auditability of risk management decisions.",
        "Cross-reference the RACI with Design Control (QAP012) for traceability and ensure the RMP is reviewed and approved as part of the management review process."
      ],
      "requirement_id": "ISO14971-4.4-02",
      "requirement_title": "Responsibilities & authorities",
      "requirement_clause": "4.4(b)",
      "tokens_used": 21812
    }
  ],
  "generated_at": "2025-09-30T15:04:58.802648"
}